Adalimumab therapy is associated with reduced risk of hospitalization in patients with ulcerative colitis.
about
Inflammatory bowel disease surgery in the biologic eraImpact of thiopurines and anti-tumour necrosis factor therapy on hospitalisation and long-term surgical outcomes in ulcerative colitisBiologics in the management of ulcerative colitis - comparative safety and efficacy of TNF-α antagonistsEfficacy and Safety of Adalimumab in Moderately to Severely Active Cases of Ulcerative Colitis: A Meta-Analysis of Published Placebo-Controlled TrialsAn indirect comparison of infliximab versus adalimumab or golimumab for active ulcerative colitisFour-year maintenance treatment with adalimumab in patients with moderately to severely active ulcerative colitis: Data from ULTRA 1, 2, and 3.Current approaches to the management of new-onset ulcerative colitis.Current and emerging biologics for ulcerative colitis.Cost-Effectiveness Analysis of 1-Year Treatment with Golimumab/Standard Care and Standard Care Alone for Ulcerative Colitis in Poland.Cost-utility analysis of 1-year treatment with adalimumab/standard care and standard care alone for ulcerative colitis in Poland.Public versus Private Drug Insurance and Outcomes of Patients Requiring Biologic Therapies for Inflammatory Bowel Disease.Therapeutic peptides in inflammatory bowel disease.Biological therapy for ulcerative colitis: an update.Biological therapy for ulcerative colitis.Conventional drug therapy for inflammatory bowel disease.Positioning Therapy for Ulcerative Colitis.How Will Evolving Future Therapies and Strategies Change How We Position the Use of Biologics in Moderate to Severely Active Inflammatory Bowel Disease.Maintenance therapy options for ulcerative colitis.Adalimumab in ulcerative colitis - efficacy, safety and optimization in the era of treat-to target.Dose de-escalation to adalimumab 40 mg every 3 weeks in patients with Crohn's disease - a nested case-control study.Systematic review with meta-analysis: comparative efficacy of immunosuppressants and biologics for reducing hospitalisation and surgery in Crohn's disease and ulcerative colitis.Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease in Patients Naïve to or Who Have Failed Tumor Necrosis Factor Antagonist Therapy.Similar Clinical and Surgical Outcomes Achieved with Early Compared to Late Anti-TNF Induction in Mild-to-Moderate Ulcerative Colitis: A Retrospective Cohort StudySafety Considerations with the Use of Corticosteroids and Biologic Therapies in Mild-to-Moderate Ulcerative Colitis.Cost of Ulcerative Colitis in Quebec, Canada: A Retrospective Cohort Study.Comparison of Infliximab and Adalimumab in Biologic-Naive Patients With Ulcerative Colitis: A Nationwide Danish Cohort Study.Comparison of infliximab with adalimumab in 827 biologic-naïve patients with Crohn's disease: a population-based Danish cohort study.ADALIMUMAB FOR ULCERATIVE COLITIS: RESULTS OF A BRAZILIAN MULTICENTER OBSERVATIONAL STUDY.Effect of Adalimumab on Clinical Outcomes and Health-related Quality of Life Among Patients With Ulcerative Colitis in a Clinical Practice Setting: Results From InspirADA.Clinical outcome of adalimumab therapy in patients with ulcerative colitis previously treated with infliximab: a Danish single-center cohort study.Escalation to weekly dosing recaptures response in adalimumab-treated patients with moderately to severely active ulcerative colitis.Targeting IL-13 as a Host-Directed Therapy Against Ulcerative Colitis
P2860
Q26745627-29CFABD0-C17F-4919-A03B-27AF396AE66AQ26771136-FF0FF1C4-0050-4715-8C65-858238FDBD13Q26999078-B398AE76-2C4A-4FA1-A237-19E1A92C78CBQ28070298-EB285E2F-D77D-4038-B3D6-26A2ADABFC68Q28079322-471D671A-16F6-45DF-82E8-D240F3C5DD03Q30844786-2E44FCEF-9D85-426B-A325-04531E0DF825Q33633288-3050DEB9-1E73-4DB0-B136-25EFDD425256Q34809305-0FEF48F7-3A6D-4221-BF65-5A013B661C31Q36095921-A1584119-871D-4802-8351-6F881B4928F9Q37322514-B5B18C8E-DBDB-4EEC-91FE-A1E9C36D82BAQ37625290-736BB4DA-84CA-443B-9CF6-4D3512C559E2Q38180807-CDBC42CE-B651-423F-AE8E-A47D7200232DQ38259532-E2EFBC07-ABCF-4972-B9BB-7A4BBD708AF8Q38262662-DD990398-3048-45BA-BA3D-5533DB4A86D9Q38293796-503D3986-9CD9-4A19-943A-469C43DFCB72Q38542903-4FC716A8-50AA-4B7D-BB33-474CADD72C37Q38719570-E6EB89AE-DB74-4D4D-BEA5-281AB57F1E48Q38848140-D14E25CC-FBC4-4CA7-9428-2ABC7969EAC2Q38895960-9887A05C-DF3E-4D5D-97A6-33D8C22919FDQ38977555-46CD1639-EFF5-4196-B08E-EF0D31005D86Q39012932-C238F7AF-3570-4B5F-ADF3-2269E7006509Q39120032-6EEE1FF9-715A-405B-8571-1E52AA90F91DQ39538749-0F02FC94-1BA2-44BC-B50B-874EA0EE1875Q40046590-774E3B20-A435-4496-B0AB-534787060FDFQ40129641-34FBC06B-3167-4BA4-82AF-72DEC8B8F4D5Q40425878-BDBBE8B6-9A9C-47BA-8AF1-67F4DC4A1224Q46070749-76BCE9FF-8640-4461-8153-23E9A47347C9Q47700572-F0FA1125-F7EF-4172-8C48-33A10032F214Q47857757-BF53D01C-EF68-453F-AE0A-EB7CB2C74827Q50566304-868FFBEA-2E6E-4E6A-AFFD-B7A0D54AE856Q53685676-DDB85289-E473-435F-A296-1CC37399FB10Q59128301-D2D05B3F-D3F4-488D-BBA8-8774F078FDAF
P2860
Adalimumab therapy is associated with reduced risk of hospitalization in patients with ulcerative colitis.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh-hant
name
Adalimumab therapy is associat ...... ients with ulcerative colitis.
@en
Adalimumab therapy is associat ...... ients with ulcerative colitis.
@nl
type
label
Adalimumab therapy is associat ...... ients with ulcerative colitis.
@en
Adalimumab therapy is associat ...... ients with ulcerative colitis.
@nl
prefLabel
Adalimumab therapy is associat ...... ients with ulcerative colitis.
@en
Adalimumab therapy is associat ...... ients with ulcerative colitis.
@nl
P2093
P1433
P1476
Adalimumab therapy is associat ...... ients with ulcerative colitis.
@en
P2093
Andreas Lazar
Bidan Huang
Jingdong Chao
Martha Skup
Naijun Chen
Nattanan Reilly
Parvez Mulani
Roopal B Thakkar
P304
110-118.e3
P356
10.1053/J.GASTRO.2013.09.032
P407
P577
2013-09-22T00:00:00Z